Long term outcome of Merkel cell carcinoma after Avelumab
This week, we’re revisiting a cornerstone study that continues to shape global cardiovascular guidelines: the Japanese Primary Prevention Project (JPPP). When its results landed, they didn't just add another data point; they fundamentally challenged the universality of low-dose aspirin therapy for primary prevention. The trial, involving 14,464 subjects aged 60-85 with hypertension, dyslipidemia, or diabetes, found no significant benefit for 100mg daily aspirin in preventing the composite of cardiovascular death, nonfatal stroke, and nonfatal MI. More critically, it highlighted a stark geographical divergence in risk and benefit that we now see reflected in nuanced, population-specific clinical guidance.
Reassessing Risk in the Japanese Population
The JPPP’s most immediate revelation was the unexpectedly low rate of cardiovascular events in the control group. This "good news" for public health in Japan created a significant methodological challenge. The trial was underpowered almost from the start, leading to an enrollment expansion and, ultimately, an early termination after a median five-year follow-up. An independent monitoring committee made the pivotal call to stop, reasoning that the diminishing probability of finding a benefit no longer justified the clear and present risk of aspirin-related hemorrhages. This decision underscored a modern trial management principle: equipoise must be actively monitored, and patient safety can supersede statistical purity.
"The decision to halt the JPPP trial early was a landmark in ethical clinical research. It demonstrated that when the baseline risk of the disease you're trying to prevent is lower than anticipated, the risk-benefit calculus shifts decisively against intervention, even one as common as aspirin." – Editorial, The Evidence Doc. Source: theevidencedoc.com/news/ | Archived: Web Archive
Quantifying the Hemorrhagic Hazard
While the primary endpoint showed no benefit, the safety signals were unambiguous. The aspirin group experienced a significantly increased burden of serious bleeding events. This data provided the hard numbers needed to move beyond vague cautions about "increased bleeding risk" to quantified, actionable hazard ratios that clinicians could weigh directly against potential benefits.
| Adverse Event | Aspirin Group (n=7220) | Control Group (n=7244) | Hazard Ratio (95% CI) |
|---|---|---|---|
| Extracranial Hemorrhage (serious) | 62 events | 34 events | 1.85 (1.22 - 2.81) |
| Intracranial Hemorrhage | 23 events | 10 events | 2.30 (1.11 - 4.79)* |
| Subarachnoid Hemorrhage | 8 events | 4 events | 2.00 (0.60 - 6.66)* |
*Confidence intervals calculated from published event counts.
The Legacy in 2026 Clinical Pathways
Today, the JPPP is not viewed in isolation but as a critical piece in a global mosaic of primary prevention research. Its legacy is evident in contemporary practice:
- Risk Stratification is Paramount: Guidelines now emphatically reject a one-size-fits-all aspirin recommendation. The focus is on calculating individual 10-year atherosclerotic cardiovascular disease (ASCVD) risk and weighing it against bleeding risk (often using tools like the HAS-BLED score).
- Geography as a Proxy for Risk: The trial cemented the understanding that baseline population risk—influenced by diet, genetics, and healthcare systems—directly impacts the net benefit of aspirin. Protocols in North America and Europe now explicitly reference regional trial data.
- Informed Shared Decision-Making: The conversation with patients has evolved. We now routinely discuss the JPPP and similar trials to illustrate that for many, the absolute benefit is vanishingly small and potentially outweighed by a tangible risk of serious bleeding.
The JPPP taught us that sometimes, the most powerful evidence is that which shows no effect, especially when it protects a population from the harms of an unnecessary, albeit familiar, medication. It moved the needle from reflexive prescribing to thoughtful, personalized restraint.